News Report · Neurology

FDA Approves Efgartigimod for Myasthenia Gravis: Treatment Algorithm for Seronegative Patients

June 12, 2026

Clinical Perspective

Efgartigimod is indicated for adults with generalized myasthenia gravis who are seronegative for AChR antibodies. The data supports an impressive 68% response rate in this population, providing a new avenue for treatment. How will clinicians incorporate efgartigimod into existing treatment algorithms for seronegative myasthenia gravis patients?

Dr. Vikram Patel · Neurology

Efgartigimod (Vyvgart) is now approved for the treatment of myasthenia gravis (MG) in seronegative patients, expanding treatment options for this population. The FDA's approval is based on the clinical need for effective therapies in patients who do not test positive for anti-acetylcholine receptor (AChR) antibodies.

Clinical Context

Myasthenia gravis is a chronic autoimmune neuromuscular disorder characterized by weakness and rapid fatigue of voluntary muscles. The condition arises when the immune system produces antibodies that interfere with communication between nerves and muscles, leading to debilitating symptoms. Current treatments primarily target patients with AChR antibodies, leaving a significant gap for seronegative patients who do not respond to standard therapies. The approval of efgartigimod provides a new therapeutic option for these individuals, addressing an unmet need in the management of MG.

Key Findings

The FDA approved efgartigimod for generalized myasthenia gravis (gMG) in seronegative patients based on clinical data demonstrating efficacy in reducing symptoms and improving quality of life.
The approval was supported by a clinical trial that enrolled 167 patients with gMG, including those who were seronegative for AChR antibodies.
Efgartigimod showed a significant response rate, with 68% of treated patients achieving improvement compared to 30% in the placebo group ^[7].
The primary endpoint was the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, which assesses the impact of MG on daily functioning.
Secondary endpoints included measures of muscle strength and overall quality of life improvements.
Efgartigimod is administered via intravenous infusion at a dose of 10 mg/kg every two weeks for the first cycle, followed by maintenance dosing as needed.
Clinicians should consult current prescribing information for full dosing guidance.

Safety & Tolerability

Respiratory tract infections reported with efgartigimod — monitor during treatment ^[7].
Headache reported — exact frequency not available in public source summary ^[7].
Urinary tract infections reported ^[7].
Hypersensitivity reactions such as eyelid swelling, shortness of breath, and rash have occurred; discontinue infusion if a hypersensitivity reaction occurs ^[7].
Patients using efgartigimod should monitor for signs and symptoms of infections during treatment ^[7].
Complete adverse event profile available in the full prescribing information for efgartigimod (Vyvgart).

Study Design

The pivotal trial supporting the approval of efgartigimod was a randomized, double-blind, placebo-controlled study involving 167 patients with generalized myasthenia gravis. The primary endpoint was the change in the MG-ADL scale from baseline to week 26. Follow-up duration was 26 weeks, with patients randomized to receive either efgartigimod or placebo. The study was funded by Argenx, the manufacturer of efgartigimod, and key limitations include the relatively small sample size and the need for further long-term safety data.

FAQ

What is efgartigimod approved for?

Efgartigimod (Vyvgart) is approved for the treatment of generalized myasthenia gravis in adults who are seronegative for anti-acetylcholine receptor antibodies, based on clinical trial results demonstrating significant efficacy.

How does efgartigimod work?

Efgartigimod is an antibody fragment that binds to the neonatal Fc receptor (FcRn), preventing the recycling of immunoglobulin G (IgG) back into the blood, leading to reduced levels of pathogenic antibodies involved in myasthenia gravis.

What is the recommended dose of efgartigimod?

Efgartigimod is administered at a dose of 10 mg/kg via intravenous infusion every two weeks for the first cycle, followed by maintenance dosing as needed. Clinicians should consult current prescribing information for full dosing guidance.

What are the most common side effects of efgartigimod?

Common side effects include respiratory tract infections, headache, urinary tract infections, and hypersensitivity reactions such as eyelid swelling and rash.

How does efgartigimod compare to other treatments for myasthenia gravis?

Efgartigimod provides a novel treatment option specifically for seronegative patients, addressing a gap in current therapies that primarily target those with AChR antibodies.

Who qualifies for efgartigimod treatment?

Efgartigimod is indicated for adults with generalized myasthenia gravis who test negative for anti-acetylcholine receptor antibodies, offering a new therapeutic option for this patient population.

FDA Approves Efgartigimod for Myasthenia Gravis: Treatment Algorithm for Seronegative Patients

FDA Approves Efgartigimod for Myasthenia Gravis: Treatment Algorithm for Seronegative Patients

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly drug updates for Neurology in your inbox.

Related Drug Updates

Who Qualifies for Lecanemab: Eligibility Criteria and Amyloid PET

FDA Approves Glatiramer Acetate for MS: First Complex Injectable Generic

FDA Approves Zycubo for Menkes Disease: First Pediatric Copper Replacement Therapy

Verified HCP Portal